相关实验视频

Updated: Jul 3, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

在泰国EGFR突变非小细胞肺癌患者的血代谢分析

Lucksamon Thamlikitkul¹, Kwanjeera Wanichthanarak^2,3, Siriphan Manocheewa²

¹Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Computational and structural biotechnology journal

|October 27, 2025

概括

血代谢物概况为诊断非小细胞肺癌 (NSCLC) 和监测治疗提供了一种非侵入性方法. 氨基酸和糖路径的关键代谢转变区分NSCLC患者,并预测对表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 的反应.

科学领域:

代谢学代谢学代谢学
在瘤学瘤学.
生物化学生物化学

背景情况:

肺癌是癌症死亡的主要原因,需要非侵入性诊断和监测工具.
代谢重编程,特别是在非小细胞肺癌 (NSCLC) 中由表皮生长因子受体 (EGFR) 突变驱动,产生独特的血代谢特征.
了解这些代谢变化对于改善患者分层和治疗策略至关重要.

研究的目的:

研究血代谢概况,用于NSCLC的非侵入性诊断和分子分类.
确定与EGFR突变相关的代谢特征和对EGFR氨酸激酶抑制剂 (TKI) 获得的耐药性.
评估血代谢物作为治疗反应生物标志物的潜力.

主要方法:

在NSCLC患者和健康对照组中进行了血代谢分析.
使用统计分析来识别歧视性代谢模式.
代谢物概况与EGFR突变状态和TKI耐药性相关.

主要成果:

氨基酸和糖代谢在NSCLC患者和健康对照人群之间显示出最显著的歧视性模式.
患有NSCLC的患者表现出高水平的甘氨酸和降低的酸和内醇水平.
氨基酸,有机酸,酸,酸和酸的明显变化使EGFR突变NSCLC差异化,并预测了TKI耐药性.

结论:

血代谢物概况揭示了与NSCLC的EGFR突变相关的生物学相关的代谢变化.
代谢特征可以识别患有EGFR TKI获得性耐药性的患者.
血代谢学作为一种微侵袭的分子分类和监测NSCLC治疗反应的工具具有前景.

关键词:

在 EGFR 基因突变.由于EGFR-TKI的耐药性,我们可以使用它.基于MS的代谢基因组.在NSCLCLC中,我们可以看到.血代谢物概况分析

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...